Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 40
- Registration Number
- NCT00918489
- Locations
- 🇩🇪
Comprehensive Cancer Center North, University Hospital Kiel, Kiel, Germany
🇩🇪Department of Hematology, Oncology, Rheumatology and Immunology, University Hospital Tübingen, Tübingen, Baden-Württemberg, Germany
🇩🇪Center for Soft Tissue Sarcoma, University Hospital Tübingen, Tübingen, Germany
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage I Small Lymphocytic LymphomaStage III Small Lymphocytic LymphomaStage IV Small Lymphocytic LymphomaStage II Small Lymphocytic LymphomaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00918723
- Locations
- 🇺🇸
Swedish Cancer Institute-Breast Center at First Hill Campus, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00910000
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00907738
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Pure Erythroid Leukemia (M6b)Adult Acute Megakaryoblastic Leukemia (M7)
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00895934
- Locations
- 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00882206
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT00875056
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT00867178
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT00858234
Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Tiziana Marangon
- Target Recruit Count
- 18
- Registration Number
- NCT00857324
- Locations
- 🇮🇹
Dipartimento Medicina Clinica e Sperimentale, Padova, Italy
🇮🇹Policlinico Universitario di Udine, Udine, Italy
🇮🇹A.O.U. S. Giovanni Battista, Torino, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.